Pharmacy Drugs
Recent Posts
- Drug Store Chains Use Flu Shots To Boost Store Traffic
- CRT May Benefit Patients wth Mild Heart Failure (CME/CE)
- New Standard Reduces Heparin Potency
- Clinical Trial Launched In India To Improve Treatment For People Bitten By Rabid Animals
- VeriChip Corporation Announces Phase II Development Of In Vivo Glucose-Sensing RFID Microchip With RECEPTORS LLC
Random Posts
- Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
- AFRESA(R) Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function In Patients Over Four Years Of Treatment
- New Study In The Journal Pediatrics(R) Reports Results Showing Superior Efficacy Of Spinosad Head Lice Treatment As Compared To Permethrin
- New Updates To AHA/ACC/SCAI Clinical Guidelines Recommend Treatment With Effient(R) For Patients With Acute Coronary Syndromes Managed With PCI
- Abbott Seeks FDA Approval Of New Dosage Strengths Of SIMCOR(R) (niacin Extended-release/simvastatin)
- Secret Plans To Criminalize Generic Medicines Could Hurt Poor Countries And People
- Electronic Brachytherapy A Viable Option For Intraoperative Radiation Therapy (IORT)
- Boehringer Ingelheim Initiates First Phase III Clinical Trial In Ovarian Cancer
- Study Links Folic Acid Supplements To Asthma
- TGen Clinical Research Services At Scottsdale Healthcare Is First To Test New Drug By Italian Firm
Do Patients With Severe Depression And A Medical Disorder Respond To Antidepressant Drugs?
Posted by: admin in Pharmacy Drugs on July 21st, 2010
This study demonstrates that over 6 weeks of treatment, patients with melancholic depression and medical comorbidity (MC) (specifically cardiovascular or endocrinological MC) had poorer treatment response and a worse functional outcome as opposed to their counterparts without MC. Interestingly, these effects were not related to various antidepressant treatment regimens.
An investigation published in the current issue of Psychotherapy and Psychosomatics by a group of German investigators explored an important clinical question: do patients with severe depression and medical disorder respond to antidepressant drugs?
In particular, this study aimed at the impact of medical comorbidity (MC) on response to antidepressant treatment over 6 weeks in diagnostic subtypes of patients with major depressive episode (MDE). In a clinical sample of 241 admitted patients with MDE, MC was assessed by medical specialists and weekly response to antidepressant treatment was assessed with the Hamilton Depression Scale (HAM-D 21). Over 6 weeks of treatment, patients with melancholic depression and MC had poorer treatment response on the HAM-D scale and a worse functional outcome (GAF) as opposed to their counterparts without MC, which was first detected after 4 weeks of treatment (p = 0.02). More specifically, subjects with melancholic depression and cardiovascular or endocrinological MC showed significantly poorer treatment response over 6 weeks. Interestingly, these effects were not related to various antidepressant treatment regimens. MC has a negative impact on treatment response in patients with melancholic depression.
Source: Psychotherapy and Psychosomatics
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.